samedan logo
 
 
spacer
home > ebr > winter 2008 > weaving a new web
PUBLICATIONS
European BioPharmaceutical Review

Weaving a New Web

The ever-changing role of the worldwide web offers new opportunities for scientific communications. Sabine Duntze at b3c communications evaluates its potential

The role of the internet in scientific communications is rapidly evolving. From a mere tool for reading and responding to email, and searching for articles and product information or protocols, we are witnessing its development into a hyper-networked platform that offers excellent opportunities for both scientists and businesses to reach wider audiences, as well as improve communications within their own communities.

Terms such as RSS, atom, XML, trackback or social web, to name just a few, are some of the buzzwords defining Web 2.0. It is all about crosslinking up-to-date content with people. A typical example of a Web 2.0 application is the so-called wiki, derived from the Hawaiian word for ‘fast’, such as the online encyclopaedia ‘Wikipedia’. Wikipedia is particularly noteworthy as it allows people to comment on and edit one another’s text, resulting in the most vital and dynamic encyclopaedia available worldwide. From a technical point of view, the content of a wiki site is selfcrosslinking, meaning that if an author mentions a specific keyword, it links automatically to other relevant pages.

In the early 2000s, wikis were increasingly adopted in businesses as collaborative software. Common uses included project communication, intranets and documentation, and they were initially meant for technical applications. Today, some companies exclusively use wikis as their collaborative software and as a replacement for static intranets. It is, therefore, not difficult to imagine that such novel technologies will also find their way into other sciences, and that laboratories may one day use a wiki-like platform to update their results and experimental protocols, for example.

SCIENTIFIC BLOGS AS A COMMUNICATIONS TOOL

A major advance in scientific communications has been achieved through blogs. A blog, a portmanteau of ‘web log’, is a website in which entries are written in chronological order, just as with online diaries. Blogs provide commentary or news on a particular subject and combine text, images and links to other blogs and web pages related to their topics. The opportunity for readers to leave comments in an interactive format is an important part of many blogs. Blogs can be easily set up and maintained and can allow scientists to reach a potentially global audience, in order to discuss technical and scientific aspects of their work and contact people working in the same field.

Communications managers will also eventually embrace the marketing opportunities opened up by blogs. They can, for example, get in touch directly with scientists at the bench to provide them with solutions for their specific problems and persuade them at a scientific level rather than with marketing jargon. However, this will have to be done carefully and not anonymously in order to avoid offending the dialogue partner. Microsoft, for example, supports a blog from the Microsoft Developer Network, in which developers provide technical details about upcoming products. Perhaps in the near future we will see biotechnology companies dedicating webspace for their own blogs, leading to enhanced customer acquisition and loyalty. At present, blogging is still far from ubiquitous, but it will surely become more and more popular as users get better acquainted with it.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
Sabine Duntze runs b3c communications, a PR agency specialising in biotech and life science communications. She has over eight years of marketing and PR experience in the biotech sector, and a strong scientific background through many years of research at the Pasteur Institute in Paris and the Max Planck Institute for Immunobiology in Freiburg, Germany. She received her PhD from the University of Braunschweig in Germany.
spacer
Sabine Duntze
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Azopharma Product Development Group, Inc

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement